Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 43

1.

Management of advanced lung cancer in resource-constrained settings: a perspective from India.

Singh N, Aggarwal AN, Behera D.

Expert Rev Anticancer Ther. 2012 Nov;12(11):1479-95. doi: 10.1586/era.12.119. Review.

PMID:
23249112
2.

Decision framework for chemotherapeutic interventions for metastatic non-small-cell lung cancer.

Berthelot JM, Will BP, Evans WK, Coyle D, Earle CC, Bordeleau L.

J Natl Cancer Inst. 2000 Aug 16;92(16):1321-9.

PMID:
10944554
3.

Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life.

Spiro SG, Rudd RM, Souhami RL, Brown J, Fairlamb DJ, Gower NH, Maslove L, Milroy R, Napp V, Parmar MK, Peake MD, Stephens RJ, Thorpe H, Waller DA, West P; Big Lung Trial participants.

Thorax. 2004 Oct;59(10):828-36.

4.

Metastatic non-small cell lung cancer: costs associated with disease progression.

Fox KM, Brooks JM, Kim J.

Am J Manag Care. 2008 Sep;14(9):565-71.

5.

Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China.

Wu B, Chen H, Shen J, Ye M.

Clin Ther. 2011 Oct;33(10):1446-55. doi: 10.1016/j.clinthera.2011.09.016. Epub 2011 Oct 11.

PMID:
21992806
6.

Cost-effectiveness analysis of cisplatin plus etoposide and carboplatin plus paclitaxel in a phase III randomized trial for non-small cell lung cancer.

Thongprasert S, Permsuwan U, Ruengorn C, Charoentum C, Chewaskulyong B.

Asia Pac J Clin Oncol. 2011 Dec;7(4):369-75. doi: 10.1111/j.1743-7563.2011.01463.x.

PMID:
22151987
7.

Treatment principles in advanced non-small-cell lung cancer.

Scott CL, Zalcberg JR, Irving LB.

Aust N Z J Surg. 1996 Oct;66(10):688-93. Review.

PMID:
8855925
8.

First-line systemic treatment of advanced stage non-small-cell lung cancer in Asia: consensus statement from the Asian Oncology Summit 2009.

Soo RA, Anderson BO, Cho BC, Yang CH, Liao M, Lim WT, Goldstraw P, Mok TS; Asian Oncology Summit.

Lancet Oncol. 2009 Nov;10(11):1102-10. doi: 10.1016/S1470-2045(09)70238-4. Review.

PMID:
19880064
9.

Cost-effectiveness and lung cancer clinical trials.

Du W, Reeves JH, Gadgeel S, Abrams J, Peters WP.

Cancer. 2003 Oct 1;98(7):1491-6.

11.
12.

Patterns, costs and cost-effectiveness of care in a trial of chemotherapy for advanced non-small cell lung cancer.

Billingham LJ, Bathers S, Burton A, Bryan S, Cullen MH.

Lung Cancer. 2002 Aug;37(2):219-25.

PMID:
12140146
13.

A systematic overview of chemotherapy effects in non-small cell lung cancer.

Sörenson S, Glimelius B, Nygren P; SBU-group. Swedish Council of Technology Assessment in Health Care.

Acta Oncol. 2001;40(2-3):327-39. Review.

PMID:
11441939
14.

Canada's Population Health Model (POHEM): a tool for performing economic evaluations of cancer control interventions.

Will BP, Berthelot JM, Nobrega KM, Flanagan W, Evans WK.

Eur J Cancer. 2001 Sep;37(14):1797-804.

PMID:
11549434
15.
16.

Granulocyte growth factors in the treatment of non-small cell lung cancer (NSCLC).

Grossi F, Tiseo M.

Crit Rev Oncol Hematol. 2006 Jun;58(3):221-30. Epub 2006 May 11. Review.

PMID:
16697211
17.

Is FDG PET/CT cost-effective for pre-operation staging of potentially operative non-small cell lung cancer? - From Chinese healthcare system perspective.

Wang YT, Huang G.

Eur J Radiol. 2012 Aug;81(8):e903-9. doi: 10.1016/j.ejrad.2012.05.006. Epub 2012 Jun 13.

PMID:
22698711
18.
20.

Chemotherapy versus best supportive care for advanced non-small-cell lung cancer.

Abang AM.

Am J Health Syst Pharm. 1996 Dec 15;53(24):2980-4. No abstract available.

PMID:
8974162

Supplemental Content

Support Center